Efficacy of high dose vitamin d on smear positive pulmonary tuberculosis treatment

Efficacy of high dose cholecalciferol on smear positive pulmonary tuberculosis treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013061610326N1

Enrollment

100

Registered

2013-08-26

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smnear positive pulmonary tuberculosis. Tuberculosis of lung, confirmed by sputum microscopy with or without culture

Interventions

Intervention 1: Control Group: Placebo (manufactured by DANA pharmaceutics) for 6 months PO for 6 months. Intervention 2: case group: vit D3 capsule: 50000IU/day PO,(manufactured by Dana Pharmaceutics

Treatment - Drugs

Control Group: Placebo (manufactured by DANA pharmaceutics) for 6 months PO for 6 months.

case group: vit D3 capsule: 50000IU/day PO,(manufactured by Dana Pharmaceutics ) for 6 months

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- age of 18-65 years 2- inclined to participate in the study 3- smear positive pulmonary tb 4- has not started antituberculous treatment 5- does not use vitamin d supplement Exclusion criteria: 1- use of antituberculous treatment regimen 2-extrapulmonary or smear negative tb 3-immunosuppresion, HIV/AIDS, renal insufficiency, hepatic failure, diabetes, organ transplant, sarcoidosis, hyperparathyroidism 5- treatment with corticosteroids, thiazides 6-symptomatic cardiac disease 7- allergy to antituberculous medications or intolerance to complete the treatment 8-concommitant consumption of drugs interacting with vitamin d levels (i.e phenytoin, phenobarbital, carbamazepin, theophylline) 9-unable to give consent to participate in the study or inability to complete the study 10-Death of the patient

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sputum conversion. Timepoint: At the initiation of treatment and six months after. Method of measurement: Sputum smear.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTasnim Eghbal Eftekhaari

Hormozgan University of Medical Sceinces, research and technology department

tasnim.eftekhaari@gmail.com, teftekhari@hums.ac.ir+98 76 1333 7192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026